Alkermes (ALKS) Stock Forecast & Price Target

Alkermes is supported by a profitable core neuroscience franchise, with management committed to profitability and rapid deleveraging even as R&D rises, while the base business is expected to support more than $300M of adjusted EBITDA ahead of the orexin launch in 2027. The positive view is further strengthened by encouraging ALKS 7290 ADHD phase 1b data in N=50, where median AISRS reductions of 14 and 19 points at 20 mg and 50 mg, plus CGI-S improvement, suggest first proof-of-concept beyond sleep disorders with mostly mild safety events and no serious TEAEs. Beyond ADHD, the orexin pipeline offers multiple near- and mid-term catalysts, including Vibrance-3 in idiopathic hypersomnia in 4Q26 and narcolepsy phase III readouts in summer-’27, with management seeing multi-$B potential and the market still not fully reflecting that optionality.

Alkermes is facing a negative setup because its valuation depends heavily on a lead orexin program that remains early stage, with efficacy and safety still needing validation in larger studies, while commercial headwinds in the injectable business could further weaken results. Erosion in the royalty business and proprietary products could pressure earnings through the remainder of the decade, and the company’s significant exposure to Medicaid adds policy-related risk under the current administration. Investors also face meaningful downside from regulatory setbacks, generic competition, manufacturing or FDA approval failures, and the possibility that ongoing R&D and SG&A outlays could require dilutive financing if operations cannot be funded internally.